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Abstract: A second-generation of purine nucleoside analogs, starting with clofarabine, has 
been developed in the course of the search for new therapeutic agents for acute childhood 
leukemia, especially for refractory or relapsed disease. Clofarabine is a hybrid of fludarabine 
and   cladribine, and has shown to have antileukemic activity in acute lymphoblastic leukemia 
as well as in myeloid disorders. As the only new antileukemic chemotherapeutic agent to enter 
clinical use in the last 10 years, clofarabine was approved as an orphan drug with the primary 
indication of use in pediatric patients. Toxicity has been tolerable in a heavily pretreated patient 
population, and clofarabine has been demonstrated to be safe, both as a single agent and in 
combination therapies. Liver dysfunction has been the most frequently observed adverse event, 
but this is generally reversible. Numerous Phase I and II trials have recently been conducted, 
and are still ongoing in an effort to find the optimal role for clofarabine in various treatment 
strategies. Concomitant use of clofarabine, cytarabine, and etoposide was confirmed to be safe 
and effective in two independent trials. Based on the promising results when used as a salvage 
regimen, clofarabine is now being investigated for its potential to become part of frontline 
protocols.
Keywords: clofarabine, pediatric acute lymphoblastic leukemia, pediatric acute myeloid 
leukemia
Introduction
Acute leukemia is the most common pediatric malignancy.1–5 Significant improve-
ments in frontline treatment protocols for both childhood acute lymphoblastic leu-
kemia (ALL)2 and acute myeloid leukemia (AML)6 have led to a marked increase in 
cure rates. Currently, a long-term remission can be achieved in about 80% of children 
affected by ALL7–11 and approximately 50% of those with AML.12–15 However, in 
cases of primary refractory disease, early systemic relapse, or multiple relapses, 
salvage regimens have a very dismal outcome.16,17 Because relapsed leukemia rep-
resents the fourth most common pediatric malignancy,18 new therapeutic options for 
this important group of patients are needed. In this context,   clofarabine is the first 
and only anticancer drug to be approved for use in children before use in adults for 
more than 10 years.19 It is primarily indicated as a single agent for the treatment 
of pediatric patients aged 1–21 years with relapsed or refractory ALL after at least 
two prior regimens, and was approved by the US Food and Drug Administration 
(FDA) in December 2004, and by the European Medicinal Evaluation Agency in 
May 2006.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Drug development and physicochemical 
properties
Clofarabine (2-chloro-2’-fluoro-2’-deoxy-9-β-D-arabinofura-
nosyladenine) is a second-generation purine nucleoside 
analog, thus acting as an antimetabolite. This molecule was 
developed to overcome the limitations   conferred by the 
  toxicity, especially dose-limiting   neurotoxicity, known with 
the structurally related analogs, cladribine and fludarabine,20–22 
and also to incorporate at the same time the best qualities 
of both congeners.23 Like other purine   analogs, clofarabine 
retains the 2-halogenated aglycone, which   renders these 
compounds resistant to deamination by   adenosine deami-
nase. In addition, clofarabine contains a second halogen 
atom, fluorine, at the 2’-position of the carbohydrate, which 
inhibits glycosidic linkage in order to protect it from bacterial 
purine nucleoside phosphorylase and from acid hydolysis.24,25 
This chemical configuration prevents release of neurotoxic 
  halogenated adenine, which is the reason for the dose-limiting 
neurotoxic side effects of similar nucleoside analogs.20 The 
stability of clofarabine in an acidic environment makes for 
a potential orally available anticancer drug, and there is 
  ongoing research in this area.24
Mechanism of action
To be able to exert its cytotoxic effect, clofarabine requires 
intracellular phosphorylation by deoxycytidine kinase (dCK) 
to its active triphosphate form, showing a greater affinity than 
fludarabine and cladribine for rate-limiting activating dCK.26,27 
Whereas the congeners of clofarabine primarily inhibit 
DNA polymerases (fludarabine) or ribonucleotide reductase 
(cladribine), clofarabine inhibits DNA synthesis and repair 
by both mechanisms.18,28,29 This mechanism leads to depletion 
of the intracellular deoxynucleotide triphosphate pool, as a 
result of which clofarabine self-potentiates the incorporation 
of clofarabine triphosphate into DNA, thereby amplifying the 
effectiveness of DNA synthesis inhibition.30,31 Additionally, 
this mechanism has an apoptotic effect via release of proapop-
totic factors, such as mitochondrial cytochrome C,25,32 caused 
by damage of the integrity of the mitochondrial membrane.33,34 
Induction of the apoptotic pathway leads to programmed cell 
death, even in nonproliferating human lymphocytes, and could 
therefore be in part the explanation for the enhanced cytotoxic 
activity of clofarabine.33,35
Pharmacokinetics and drug metabolism
The highest concentration of clofarabine in plasma occurs 
at the end of infusion, as known from other nucleoside 
  analogs.36 The inhibition rate of DNA synthesis ranged from 
75%–95% (at the end of infusion) when 22.5–55 mg/m2 
doses have been administered.31 When lower doses (22.5 and 
30 mg/m2) were administered, a partial recovery of inhibition 
of DNA synthesis was observed after 24 hours, whereas at 
higher dose levels (40 and 55 mg/m2) inhibition was main-
tained, demonstrating a dose-dependent effect on degree and 
maintenance of DNA synthesis inhibition during therapy with 
clofarabine.37 Patient-dependent parameters shown to influence 
the pharmacokinetic profile of clofarabine are body weight and 
white blood cell (WBC) count. While the observed increase in 
clofarabine plasma concentration in cases of a WBC decrease 
does not seem to be significant enough to justify modification 
of the treatment regimen as a function of WBC count, admin-
istration of the dose on a per square meter or per body weight 
basis is crucial.38 Clofarabine is 47% bound to plasma protein, 
of which 27% is serum albumin, resulting in wide tissue dis-
tribution.39 Once intracellular, accumulation of clofarabine 
triphosphate, the active form of clofarabine, in the blasts of 
patients with refractory leukemia has been demonstrated in 
several studies.37,38 Because the highest concentrations of dCK 
are found in lymphoid tissues, a sustained antileukemic activity 
would be expected,38 enhanced by the prolonged intracellular 
half-life of 24 hours for clofarabine triphosphate, in contrast 
with fludarabine and cladribine, which have median half-lives 
of only 8–10 hours.18,37 Based on 24-hour urine collection, 
49%–60% of the dose is excreted in the urine unchanged. 
Metabolism via the cytochrome P450 system has not been 
demonstrated, so the pathways for nonrenal excretion of 
clofarabine remain unknown for the moment.37 The terminal 
half-life of clofarabine is estimated to be 5.2 hours.18
Clinical efficacy
Preclinical studies
Initial interest in performing clinical efficacy and safety 
studies for clofarabine was rather subdued, as a result of the 
unfavorable toxicity-efficacy ratio observed for fludarabine 
and cladribine. The antileukemic activity of fludarabine has 
been established, but the toxic side effects at therapeutic dos-
age were not acceptable (death of 4/9 patients due to severe 
neurologic side effects in one study).40 Because clofarabine 
has been shown to be even more lipophilic than cladribine,41 
it has been presumed that its neurotoxicity would be at least 
as severe as that for the other nucleoside analogs, attribut-
ing at most a role for the treatment of lymphoproliferative 
disorders in the central nervous system.31 Surprisingly, the 
accumulation of clofarabine in brain tissue of mice was found 
to be lower than for cladribine.42 The few differences in the 
chemical structure were decisive.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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The early intention of Kantarjian et al in 1992 to conduct 
a Phase I study in humans,23 after the synthesis of clofarabine 
earlier that year,43 was delayed when the FDA requested that 
animal toxicology studies in two animal models (mice and 
dogs) be done first. These studies identified a safe starting 
dose of 15 mg/m2 daily for five days (1/10th of LD10 in mice) 
for human Phase I clinical trials (Kantarjian, unpublished 
data),23 approved by the FDA in 1998.23
early clinical studies
The first Phase I study of clofarabine was performed in 
51 adult patients with refractory/relapsed solid or hematologic 
malignancies to define the dose-limiting toxicity (DLT) of the 
drug and to determine the maximum tolerated dose (MTD) for 
acute and chronic leukemias, myeloma, and solid tumors.44 
The MTD for patients with solid tumors was determined to 
be 2 mg/m2, showing that the starting dose of 15 mg/m2 was 
too high, with the DLT being   myelosuppression. However, 
the overestimation of the safe starting dose is known to be 
due to the differing pharmacokinetic profiles for the drug 
in dogs and humans.45,46 On the other hand, the MTD for 
acute leukemia was determined at 40 mg/m2/day, with the 
DLT being hepatotoxicity.44 This marked difference of a 
20-fold higher MTD in patients with leukemia versus those 
with solid tumors was unattended and exceeded the usual 
difference of a two- to seven-fold higher MTD for other 
agents. Because transient myelosuppression and cytopenia 
during the treatment of leukemia are unavoidable, these are 
not considered to be conventional dose-limiting side effects. 
Thirteen of 32 patients with leukemia in this Phase I study 
had ALL. Their overall response rate was 15%, consisting 
of one complete remission (CR) and one CR without platelet 
recovery (CRp).
Based on these results, a parallel Phase I trial for   pediatric 
patients with advanced leukemia was opened, including 
25 patients affected by relapsed or refractory leukemia 
(17 ALL, eight AML).47 Six dose levels (11.25 mg/m2, 
15 mg/m2, 30 mg/m2, 40 mg/m2, 52 mg/m2, and 70 mg/m2) 
were investigated to define the DLT and MTD for children. The 
MTD was established to be 52 mg/m2/day for five days, and 
the DLT was identified to be reversible Grade 3   hepatotoxicity 
and skin rash. Hematopoietic stem cell transplantation (HSCT) 
either before (n = 9) or after (n = 7) clofarabine did not cause 
increased toxicity. The majority of the patient cohort (20/25) 
received more than one cycle (12 patients had two cycles, 
seven had three cycles, and two patients had eight cycles), 
and this was not associated with cumulative hepatotoxicity. 
The overall response (OR) rate was 32%, with five patients 
achieving a CR (ALL, n = 4; AML, n = 1) and three having a 
partial response (PR, ALL, n = 1; AML, n = 2).
Two open-label, multicenter, nonrandomized Phase II 
trials were opened in 2002, aiming to establish the   efficacy 
and safety profile of clofarabine in pediatric patients 
(age 1–21 years at diagnosis), affected by ALL (median age 
12 years) or AML (median age 13 years), and with relapsed 
disease or disease refractory to standard therapies.19,48
The study of the efficacy of clofarabine in ALL enrolled 
61 patients who had previously received a median of three 
(range 2–6) treatment regimens, and nearly a third of these 
patients had received at least one prior HSCT regimen 
(30%). Immunophenotyping showed that 79% of patients 
were B precursor/B cell lineage, 8% were T cell lineage, 
and 13% had acute leukemia with other/unknown cell 
  lineage.19 All patients received intravenous (IV) clofarabine 
52 mg/m2/day as a single agent on five consecutive days for 
up to 11 cycles (median two). The median time between two 
cycles was 28 (range 12–55) days. The results of this trial 
showed an OR rate of 20% (seven CR and five CRp), and 
an additional PR rate of 10%. CR patients who proceeded 
to HSCT maintained their CR for a median period of seven 
months. The median CR duration was only two months when 
treatment with clofarabine was not followed by HSCT. Nine 
patients proceeded to transplantation after clofarabine ther-
apy. The most frequently observed Grade $ 3 adverse events 
were febrile neutropenia (49%), followed by hypokalemia 
(46%), elevated aspartate transaminase (38%) or alanine 
transaminase (43%), anorexia (20%), hypotension (18%), 
nausea (16%), hyperbilirubinemia (16%), and neutropenia 
(15%). Systemic inflammatory response-like or cytokine 
release-like events (including respiratory distress, fever, 
and hypotension), skin rash, and hand-food syndrome were 
also observed.19
The results of this study were the basis for the accelerated 
approval of clofarabine in the US and in Europe for the treat-
ment of pediatric ALL in at least its second relapse. Similar 
trials were initiated and broadly confirmed the existing data, 
eg, in the similarly designed European Phase II nonrandom-
ized, open-label study, in which 96 courses of clofarabine 
at the same dosage of 52 mg/m2/day were administered to 
53 pediatric patients with relapsed/refractory ALL.49 In 
that study, an OR rate of 26% was achieved (six CR, seven 
CRp, and one PR). Four patients (one CR and three CRp) 
proceeded to HSCT. The most frequent adverse events were 
febrile neutropenia (50%), seizures (4%), and sepsis and 
hepatotoxicity each in 3%. The lower number of hepatic 
adverse events in comparison with the US trial may have Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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been due to a more heavily pretreated patient population in 
the US study (median three versus two prior regimens).49
Results for the AML arm in the study by Jeha et al have 
recently been published, describing a treatment regimen 
conducted in 42 patients with refractory or relapsed AML, 
where clofarabine was used as a single agent at 52 mg/m2/day 
for five consecutive days.48 In this study, the OR rate was 
26%, with one CRp and 10 PR. Six of the responders were 
patients who had been refractory to the preceding therapy. 
Thirteen patients, of whom seven were responders, proceeded 
to HSCT. The median response duration was 20 weeks, 
whereas the survival duration of transplanted patients ranged 
from 24 to $160 weeks. The overall toxicity profile was 
comparable with that observed in other studies (Table 1), but 
five patients died as a result of an adverse event.48
Postmarketing combination studies
In view of the encouraging results of the trials with   clofarabine 
as a single agent, and with regard to its mechanism of action, 
several studies investigated the possibility of incorporating 
clofarabine into rational combinations with conventional 
anticancer drugs.50,51
Clofarabine combined  
with alkylating agents
An increased cytotoxic effect could be expected using a 
combination of clofarabine and alkylating agents, such as 
cyclophosphamide. Repair of the DNA damage caused by 
the alkylating agents would be impeded due to the ability 
of   clofarabine to inhibit DNA synthesis/repair. A synergis-
tic effect was demonstrated first in in vitro studies,28 and 
was successively confirmed in clinical trials. A Phase I 
  dose-escalating pilot study of clofarabine used in   combination 
with   cyclophosphamide and etoposide was conducted by 
Hijiya et al to determine the MTD and DLT for this new treat-
ment regimen in pediatric patients with refractory or relapsed 
acute leukemia.52 The preliminary data for this Phase I study 
were reported while a Phase II study of the same treatment 
regimen was already ongoing.52 In the Phase I trial, 25 patients 
(20 with ALL and five with AML) were enrolled, and five 
dosing cohorts were evaluated using escalating doses of 
clofarabine 20–40 mg/m2/day, etoposide 75–100 mg/m2/day, 
and cyclophosphamide 340–440 mg/m2/day.52 An OR rate 
of 64% was achieved (ALL 55%, AML 100%), consisting 
of a CR in 10 patients (nine with ALL, one with AML) and 
a CRp in six patients (two with ALL 2, four with AML). 
Of these 16 patients, nine proceeded to HSCT; the median 
duration of remission for these patients was 18.2 weeks. The 
response rate was 69% in patients with B cell precursor ALL, 
documented in 20% of patients with T cell ALL. A MTD 
was not reached, and the recommended Phase II doses were 
clofarabine 40 mg/m2/day, cyclophosphamide 440 mg/m2/day, 
and etoposide 100 mg/m2/day. The most common adverse 
events (all grades) were nausea (80%), vomiting (72%), 
febrile neutropenia (64%), pyrexia (48%), diarrhea (44%), 
skin rash (40%), and transaminase elevation (38%). Because 
of unexpected hepatotoxicity (three cases of veno-occlusive 
disease and one of hyperbilirubinemia), the Phase II   portion 
of the study was amended to exclude patients with, eg, viral 
hepatitis, liver cirrhosis, hyperbilirubinemia, and prior 
HSCT.52 This trial is evaluating the safety and efficacy of this 
combination regimen in ALL patients, and is ongoing.
Table 1 Patients with Grade $ 3 adverse events in all cycles
Reference study
Phase I47 Phase II  
ALL19
Phase II  
AML48
CLO-CPM- 
VP-1652
CLO-CPM- 
VP-1653
Adverse event
Hypertransaminasemia 28% 43% 43% 38% 24%
Hyperbilirubinemia 16% 12% 0%
Febrile neutropenia n.i. 49% 55% 64% n.i.
infections n.i. 69% 67% 72% 32%
Nausea/vomiting 16% 16% 17% 12% n.i.
Hypokalemia n.i. 46% 40% 24% n.i.
Pericardial effusion n.i. 29% 39% n.i. 0%
Decrease in left ventricular systolic function n.i. 17% 32% n.i. 0%
Skin rash  4% 10% n.i. 0% 0%
Hypotension n.i. 18% 17% n.i. n.i.
Hypertension n.i. 10% n.i. n.i. n.i.
Ae-related death (n) 0% 8% (5) 12% (5) 12% (3) 0%
Abbreviations: Ae, adverse events; CLO, clofarabine; CPM, cyclophosphamide; vP-16, etoposide; n.i., not indicated.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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The second open-label, multicenter trial   investigating the 
possible complementary effect of a   clofarabine-  cyclophosp
hamide-etoposide combination was a   nonrandomized Phase 
II efficacy and safety study performed by Locatelli et al.53 
This study included 25 pediatric patients (median age 
12.5 years) with either refractory (n = 17) or multiple 
relapsed (n = 8) ALL. The treatment regimen,   administered 
on five consecutive days, comprised a two-hour IV 
infusion of   clofarabine 40 mg/m2/day, followed by a one-
hour infusion of cyclophosphamide 400 mg/m2/day and a 
two-hour infusion of etoposide 150 mg/m2/day. In this trial, 
an OR rate of 56% was achieved, consisting of 13 patients 
(52%) achieving a CR and another achieving a CRp (4%). 
For more than half of the CR patients (53%), the remission 
duration was sufficient to allow them to proceed to HSCT. 
As in the study by Hijiya et al the probability of reaching 
a CR/CRp was significantly higher in patients with B cell 
precursor ALL (76%) than in those with T lineage ALL 
(12%). The most frequent adverse events were febrile neu-
tropenia, reversible liver toxicity, and mucositis. No case of 
veno-occlusive   disease, tumor lysis syndrome, or cytokine-
release syndrome was reported. This favorable tolerability 
may be due to the careful   prophylaxis regimen used in this 
trial, including   prophylactic steroid administration to prevent 
  cytokine-release syndrome when .30 × 109 blast cells/L in 
peripheral blood was present at the time of treatment.
Clofarabine combined with other 
nucleoside analogues
Playing on the concept that clofarabine effectively inhibits the 
ribonucleotide reductase, an association with the pyrimidine 
analog, cytarabine, was performed.54 In in vitro experiments, 
it has been observed that pretreatment with clofarabine leads 
to enhanced intracellular cytarabine triphosphate levels via 
indirect upregulation of dCK, caused by a decreased dNTP 
pool (ribonucleotide reductase inhibition).54 Phase I–II   studies 
of clofarabine in combination with cytarabine in an adult 
patient population with relapsed or refractory acute leukemia 
have been performed.55,56 Clofarabine 40 mg/m2/day was 
given for five days as a one-hour IV infusion, followed four 
hours later by cytarabine 1 g/m2/day as a two-hour   infusion for 
five days. This treatment regimen was shown to be safe and 
effective in 32 patients with relapsed leukemia (two with ALL 
and 25 with AML, four with high-risk myelodysplastic syn-
drome, and one with blast-phase chronic myeloid leukemia).55 
The same investigators have also investigated a salvage regi-
men of idarubicin-clofarabine ± cytarabine for adult patients 
with AML.57 A single case report of clofarabine-cytarabine 
in a nine-year-old boy with multiple relapsed T cell ALL 
showed a complete morphologic and cytogenetic remission 
using one cycle of this combination.58
A recently closed pediatric Phase I–II study has 
  investigated the safety of clofarabine-cytarabine in   pediatric 
patients with AML in first relapse and ALL in at least second 
relapse.59 In this trial, a fixed cytarabine dose of 1 g/m2 was 
administered from days 1–5 of the cycle, whereas clofara-
bine was administered on days 2–6 at varying doses. As in 
the adult study, clofarabine was given four hours before 
the infusion of cytarabine, taking advantage of the syner-
gistic mechanism of action of these agents. The first cohort 
included 10 patients (eight with ALL and two with AML), 
and the starting dose of clofarabine was the adult single-
agent MTD of 40 mg/m2. This dosage could be escalated to 
52 mg/m2, which was then administered to the second patient 
cohort (three with ALL and seven with AML). The doses 
used at the end of the Phase I trial have been defined to be 
the MTD for this drug   combination. The observed toxicity 
profile was comparable with that previously described. It 
was concluded that the clofarabine-cytarabine combination 
is safe and tolerable.59
Started in 2008, an ongoing Phase II randomized trial of 
clofarabine-cytarabine versus conventional induction therapy 
(cytarabine-daunorubicin-etoposide) in patients with newly 
diagnosed AML is investigating a role for clofarabine in the 
early phase of antileukemic treatment. A more favorable 
toxicity profile could be expected using this combination in 
a patient population not having undergone chemotherapy 
previously, and hopefully with a better final outcome.
Clofarabine-anthracycline  
combination therapy
The ability of clofarabine to inhibit DNA strand elongation 
makes it suitable for use in combination with anthracyclines, 
thereby taking advantage of the anthracycline’s ability to 
induce DNA intercalation and strand breaks. Early data 
for a possible synergistic effect have been reported from 
an in vitro study using oxaliplatin-fludarabine.60 A Phase 
I/II study of clofarabine in combination with cytarabine 
and liposomal daunorubicin given to children affected by 
relapsed/  refractory AML is ongoing.
Clofarabine as a conditioning  
regimen for HSCT
In an attempt to enhance the cytotoxic effect of clofarabine 
whilst reducing treatment-related toxicity, clofarabine is also 
being investigated as part of conditioning regimens.61 A Phase I Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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trial at the St Jude Children’s Research Hospital is   presently 
determining the MTD and DLT of clofarabine when used in 
combination with melphalan and thiotepa in a pretransplant 
conditioning regimen. Several studies integrating clofarabine 
into conditioning regimens are also ongoing in adults.
Toxicity profile of clofarabine
On the basis of the studies reported to date, the most 
common Grade $ 3 adverse events with clofarabine are 
  hepatotoxicity (elevated transaminases and/or hyperbili-
rubinemia), febrile neutropenia, and infections. A detailed 
description of the adverse event distribution in the main 
studies of   clofarabine in pediatric patients is outlined in 
the Table 1.
Hepatotoxicity was the DLT for clofarabine in the Phase I 
trial,47 and was observed in all Phase II studies, both in single-
use and in combination regimens.19,48,52,53 Hepatic dysfunction 
was usually reversible, showing a peak around days 5–7, 
and recovery by days 15–16 (,Grade 2).18,19 In some cases, 
  however, severe and potentially life-threatening hepatotoxic-
ity occurred with the use of clofarabine. In the Phase II study, 
performed on the basis of the Phase I   combination study of 
clofarabine-cyclophosphamide-etoposide by Hijiya et al three 
of the first eight patients enrolled developed veno-occlusive 
disease, and there was one case of hyperbilirubinemia. 
Thereafter, the Phase II portion of the trial was amended as 
described above and so far, none of the further seven patients 
enrolled have experienced severe hepatotoxicity.52 As a 
result of the studies performed until now, close monitoring 
of liver function is recommended during and after therapy 
with clofarabine, and the potentially cumulative hepatotoxic-
ity should be considered when using other drugs known to 
compromise liver function.
In the Phase II study by Jeha et al several cases of 
  systemic inflammatory response or cytokine release-like 
events, capillary leak syndrome, and severe tumor lysis 
syndrome, including a fatal outcome, have been   associated 
with the use of clofarabine.19 To prevent this type of 
adverse event, Locatelli et al performed a study in which 
steroids have been administered in a prophylactic manner 
when .30 × 109 blasts/L were counted in peripheral blood 
at the time of treatment. None of the enrolled patients 
  experienced tumor lysis, cytokine-release, or systemic 
inflammatory syndrome.53
In addition, to prevent infection-related   complications, 
a broad-spectrum antibiotic, antiviral, and antifungal 
  prophylactic regimen should be instituted in all patients 
treated with clofarabine.
Resistance to clofarabine
Although the efficacy of clofarabine is not restricted to a 
specific leukemia subtype, and CRs have been achieved in 
both AML and ALL patients, some differences in response 
pattern have been seen. It is conspicuous that the OR rate 
in the Hijiya’s study group was 69% in patients with B cell 
  precursor ALL (CR = 9), and only 20% in five patients 
with the T lineage subtype (CRp = 1).52 An even larger 
gap in terms of response was reported by Locatelli et al 
who reported that a CR/CRp was achieved by 76% of 
children with B cell precursor ALL, whereas only 12% 
of those with T cell leukemia responded to therapy with 
clofarabine.53 These data could be indicative of a   possible 
resistance   mechanism inherent in T lineage leukemic 
blasts. An   observation   supporting such a hypothesis is 
the conclusion of an in vitro study, where clofarabine 
appeared to be slightly more effective in B lymphoblasts 
than in T blasts.62 Furthermore, pharmacologic studies have 
reported cross-resistance of clofarabine-resistant cell lines 
to other antimetabolites, such as cytarabine or fludarabine, 
which are phosphorylated by dCK.32 Reduced dCK activity 
has been shown to be directly correlated with resistance to 
clofarabine, because those cell lines did not consistently 
form detectable levels of triphosphates.31 dCK deficiency 
has been demonstrated at the level of enzymatic activity, 
at the protein level, and also at the mRNA expression level 
for resistant cell lines.31 However, the hypothesis that DNA 
methylation might be responsible for the decreased dCK 
level could not be confirmed, and no mutations in the cod-
ing region of the dCK have been detected so far.32 Further 
studies will be necessary to explain resistance mechanisms 
to clofarabine, and to indicate consequently which leukemic 
form is sensitive to therapy with clofarabine and for which 
ones alternative treatment strategies are needed.
Summary and future directions
Clofarabine is a recent second-generation purine adenosine 
analog with important therapeutic efficacy not restricted to 
a specific leukemic subtype, and with responses obtained 
even in patients with prior refractory disease. It has been 
shown to be safe when used as a single agent and in rational 
combinations with conventional chemotherapeutic drugs. 
The toxicity profile is tolerable in a heavily pretreated patient 
population. A role for clofarabine in frontline protocols is 
presently being investigated. Other studies are exploring the 
potential of clofarabine to become a component of condition-
ing regimens for hematopoietic stem cell transplantation. 
Defining the optimal time point and the most appropriate Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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treatment regimen for the use of clofarabine will be the 
subject of future studies.
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